Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas

Front Oncol. 2022 Mar 10:12:860964. doi: 10.3389/fonc.2022.860964. eCollection 2022.

Authors

Zhanjun Guo¹, Heng-Hong Li², Yih-Horng Shiao³

Affiliations

¹ Department of Immunology and Rheumatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
² Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States.
³ United Department of Commerce, States Patent and Trademark Office, Alexandria, VA, United States.

No abstract available

Keywords: Hepatocellular carcinomas; PD-1; PD-L1; bioinformatics; biomarkers; immune-checkpoint inhibitors; immunotherapies.

Publication types

Editorial